Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers

Nucleic Acids Research

Volumn 43, Issue 19, 2015, Pages 9123-9132

  Subramanian, Romesh R ^a,c   Wysk, Mark A ^a   Ogilvie, Kathleen M ^b,d   Bhat, Abhijit ^b,e   Kuang, Bing ^b   Rockel, Thomas D ^b,f   Weber, Markus ^b,g   Uhlmann, Eugen ^b,h   Krieg, Arthur M ^a  

^a Translate Bio Inc   (United States)

^b PFIZER INC   (United States)

^c ALEXION PHARMACEUTICALS   (United States)

^d aTyr Pharma   (United States)

^e IPSEN   (France)

^f MILTENYI BIOTEC GMBH   (Germany)

^g Bayer Industry Services GmbH and Co OHG   (Germany)

^h AdiuTide Pharmaceuticals GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2',4' CONSTRAINED ETHYL; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; CHEMICAL COMPOUND; CLEAVABLE LINKER; LOCKED NUCLEIC ACID; MICRORNA 122; MISCELLANEOUS DRUGS AND AGENTS; MULTI TARGETING OLIGONUCLEOTIDE; OLIGONUCLEOTIDE; POLYMER; UNCLASSIFIED DRUG; MICRORNA; MIRN122 MICRORNA, MOUSE;

ANIMAL TISSUE; ANTISENSE EFFICACY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; FEMALE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RNA BINDING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; DIMERIZATION; GENETICS; HUMAN; LIVER; METABOLISM; TISSUE DISTRIBUTION; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; DIMERIZATION; FEMALE; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; TISSUE DISTRIBUTION;

EID: 84959387101     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkv992     Document Type: Article

References (21)

1. Kolse,R., Krainer,A.R. and Altman,S. (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov., 11, 125-140.
2. Lennox,K.A. and Behlke,M.A. (2011) Chemical modification and design of anti-miRNA oligonucleotides. Gene Therapy, 18, 1111-1120.
3. Kurreck,J., Wyszko,E., Gillen,C. and Erdmann,V.A. (2002) Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res., 30, 1911-1918.
4. Seth,P.P., Siwkowski,A., Allerson,C.R., Vasquez,G., Lee,S., Prakash,T.P., Wancewicz,E.V., Witchell,D. and Swayze,E.E. (2009) Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem., 52, 10-13.
5. Stanton,R., Sciabola,S., Salatto,C., Weng,Y., Moshinsky,D., Little,J., Walters,E., Kreeger,J., DiMattia,D., Chen,T. et al. (2012) Chemical modification study of antisense gapmers. Nucleic Acid Ther., 22, 344-359.
6. Straarup,E.M., Fisker,N., Hedtjärn,M., Lindholm,M.W., Rosenbohm,C., Aarup,V., Hansen,H.F., Ørum,H., Hansen,J.B. and Koch,T. (2010) Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res., 38, 7100-7111.
7. Murray,S., Ittig,D., Koller,E., Berdeja,A., Chappell,A., Prakash,T.P., Norrbom,M., Swayze,E.E., Leumann,C.J. and Seth,P.P. (2012) TricycloDNA-modified oligo-2′-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues - a comparative study of oligonucleotide length, design and chemistry. Nucleic Acids Res., 40, 6135-6143.
8. Obad,S., dos Santos,C.O., Petri,A., Heidenblad,M., Broom,O., Ruse,C., Fu,C., Lindow,M., Stenvang,J., Straarup,E.M. et al. (2011) Silencing of microRNA families by seed-targeting tiny LNAs. Nature Genet., 43, 371-378.
9. Watanabe,T.A., Geary,R.S. and Levin,A.A. (2006) Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides, 16, 169-180.
10. Koller,E., Vincent,T.M., Chappell,A., De,S., Manoharan,M. and Bennett,C.F. (2011) Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res., 39, 4795-4807.
11. Geary,R.S., Yu,R.Z. and Levin,A.A. (2001) Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr. Opin. Investig. Drugs, 2, 562-573.
12. Stein,C.A., Hansen,J.B., Lai,J., Wu,S., Voskresenskiy,A., Høg,A., Worm,J., Hedtjärn,M., Souleimanian,N., Miller,P. et al. (2010) Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res., 38,e3.
13. Efler,S.M., Zhang,L., Noll,B.O., Uhlmann,E. and Davis,H.L. (2005) Quantification of oligodeoxynucleotides in human plasma with a novel hybridization assay offers greatly enhanced sensitivity over capillary gel electrophoresis. Oligonucleotides, 15, 119-131.
14. Elmen,J., Lindow,M., Schütz,S., Lawrence,M., Petri,A., Obad,S., Lindholm,M., Hedtjärn,M., Hansen,H.F., Berger,U. et al. (2008) LNA-mediated microRNA silencing in non-human primates. Nature, 452, 896-899.
15. Esau,C., Davis,S., Murray,S.F., Yu,X.X., Pandey,S.K., Pear,M., Watts,L., Booten,S.L., Graham,M., McKay,R. et al. (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab., 15, 87-98.
16. Burdick,A.D., Sciabola,S., Mantena,S.R., Hollingshead,B.D., Stanton,R., Warneke,J.A., Zeng,M., Martsen,E., Medvedev,A., Makarov,S.S. et al. (2014) Sequence motifs associated with hepatotoxicity of locked nucleic acid-modified antisense oligonucleotides. Nucleic Acids Res., 42, 4882-4891.
17. Eckstein,F. (2014) Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther., 6, 374-387.
18. Eder,P.S., DeVine,R.J., Dagle,J.M. and Walder,J.A. (1991) Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res. Dev., 1, 141-151.
19. Juliano,R.L., Ming,X., Carver,K. and Laing,B. (2014) Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology. Nucleic Acid Ther., 24, 101-113.
20. Prakesh,T.P., Graham,M.J., Yu,J., Carty,R., Low,A., Chappell,A., Schmidt,K., Zhao,C., Aghajan,M., Murray,H.F. et al. (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res., 42, 8796-8807.
21. Bhagat,L., Putta,M.R., Wang,D., Yu,D., Lan,T., Jiang,W., Sun,Z., Wang,H., Tang,J.X., La Monica,N. et al. (2011) Novel oligonucleotides containing two 3′-ends complementary to target mRNA show optimal gene-silencing activity. J. Med. Chem., 54, 3027-3036.